Mantle Cell Lymphoma | Specialty

The OncLive Mantle Cell Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on mantle cell lymphoma treatment. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, therapeutic advances, and ongoing research in mantle cell lymphoma.

Glofitamab/Obinutuzumab Regimen Produces Early, Durable Responses in Relapsed/Refractory Mantle Cell Lymphoma

December 10th 2022

Glofitamab administered as a fixed 12-cycle regimen 7 days after obinutuzumab pretreatment elicited high, early, and durable responses in patients with relapsed/refractory mantle cell lymphoma who had undergone prior BTK inhibitor therapy.

Brody Previews ASH 2022 Data With Pirtobrutinib, CAR T-cell Therapy, and Glofitamab in MCL

December 8th 2022

Dr Brody previews mantle cell lymphoma data being presented at the 2022 ASH Annual Meeting and Exposition, including promising data on pirtobrutinib from the BRUIN trial, the potential for CAR T-cell therapy as evidenced in the ZUMA-2 trial, and how immunotherapies such as glofitamab are expanding the treatment paradigm.

BTK Inhibitor Failure Signals Unmet Need for a Standard of Care in Relapsed/Refractory MCL

November 18th 2022

Improved mantle cell lymphoma treatments are necessary for patients who have relapsed on or are refractory to BTK inhibitors, according to findings from SCHOLAR-2, a multicenter, retrospective chart review of European patients with MCL who relapsed following or were intolerant to BTK inhibitors.

Ibrutinib Demonstrates Real-world ORR Benefit in Relapsed/Refractory MCL

November 17th 2022

Ibrutinib therapy remains an effective treatment, particularly in the second line, in patients with relapsed/refractory mantle cell lymphoma.

Dr. Goy on the Clinical Implications of Treating Indolent MCL

November 15th 2022

Andre H. Goy, MD, discusses the clinical implications of treating indolent mantle cell lymphoma.

Dr. Epstein-Peterson on Pivotal Clinical Trials in MCL

November 14th 2022

Zachary Epstein-Peterson, MD, discusses pivotal clinical trials in the treatment of patients with mantle cell lymphoma.

Dr. Epstein-Peterson on the Importance of Treatment Sequencing Decisions in MCL

November 4th 2022

Zachary Epstein-Peterson, MD, discusses the importance of treatment sequencing decisions in mantle cell lymphoma.

Novel Therapies Provide a Wealth of Individualized Treatment Options in CLL and MCL

October 20th 2022

Farrukh Awan, MD, discusses new agents under investigation in chronic lymphocytic leukemia and mantle cell lymphoma and emphasizes the importance of weighing each drug’s risks and benefits against individual patient needs and preferences to make informed decisions.

Dr. Goy on Discrepancies in Clinical Trial vs Real-World MCL Treatment

October 17th 2022

Andre H. Goy, MD, discusses clinical trial vs real-world treatments in patients with mantle cell lymphoma.

Treatments for MCL Continue to Progress

October 14th 2022

As research and treatment options for patients with mantle cell lymphoma continue to expand, the development of risk-adapted therapies for the 3 primary subtypes—blastoid, smoldering, and classic broad-spectrum—represents a crucial next step in the field.

Dr. Danilov on the Next Steps for Researching Noncovalent BTK Inhibitors in MCL

October 11th 2022

Alexey V. Danilov, MD, PhD, discusses the next steps for researching noncovalent BTK inhibitors in mantle cell lymphoma.

Frontline BR Plus ASCT and Maintenance Rituximab Demonstrates Activity in Transplant-Eligible MCL

October 10th 2022

Bendamustine plus rituximab followed by autologous stem cell transplant and maintenance rituximab led to comparable outcomes defined by progression-free survival and objective response rate compared with R-CHOP/R-DHAP and ASCT as induction therapy in patients with mantle cell lymphoma.

Dr. Danilov on the Differences Between Covalent and Noncovalent BTK Inhibitors in MCL

October 7th 2022

Alexey V. Danilov, MD, PhD, discusses the key differences between covalent and noncovalent BTK inhibitors in mantle cell lymphoma.

Rituximab Maintenance Following First-line BR/R-CHOP Offers Significant Real-World Benefits in MCL

September 23rd 2022

Maintenance treatment with rituximab following first-line treatment with rituximab plus bendamustine or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone produced an overall survival benefit in older patients with mantle cell lymphoma.

NVG-111 Generates Early Efficacy With Manageable Safety in Relapsed/Refractory CLL, MCL

September 14th 2022

The ROR1-targeting bispecific T-cell engager NVG-111 elicited promising responses with a manageable safety profile in patients with relapsed/refractory chronic lymphocytic leukemia or mantle cell lymphoma.

Brexu-cel Elicits Sustained 3-Year Responses in Relapsed/Refractory MCL

September 14th 2022

Treatment with brexucabtagene autoleucel drove durable responses in patients with relapsed/refractory mantle cell lymphoma, particularly those with minimal residual disease negativity at 6 months.

Late Effects Arise Irrespective of High-Dose Chemotherapy and ASCT Status in MCL

September 13th 2022

Intensive first-line treatment with high-dose chemotherapy and autologous stem cell transplant was not associated with higher rates of late effects compared with outcomes from less intensive therapies in patients with mantle cell lymphoma.

Dr. Kumar on Treatment Considerations with BTK Inhibitors in MCL

September 9th 2022

Anita Kumar, MD, discusses considerations for the use of second-line BTK inhibitors in patients with mantle cell lymphoma who progress on BTK inhibitors.

Maintenance Rituximab Prolongs Time to Next Treatment, OS in MCL

August 17th 2022

Maintenance rituximab following first-line bendamustine plus rituximab or a combination of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone prolonged first-line treatment benefits and improved survival outcomes vs either induction regimen alone.

New Acalabrutinib Tablet Formulation Approved for Current Indications, Including CLL, SLL, and MCL

August 5th 2022

The FDA has approved a new tablet formulation of acalabrutinib for all current indications, including adult patients with chronic lymphocytic leukemia, small lymphocytic lymphoma, and for those with relapsed or refractory mantle cell lymphoma.